Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/06/2012US8304390 Administering to a patient taurolidine, taurultam or a mixture as antitumor metastasis agent
11/06/2012US8304385 Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
11/06/2012US8304234 Compositions and methods for delivery of genetic material
11/06/2012US8304217 Stabilized dihydrolipoic acid and method of producing same
11/06/2012US8304182 Methods of identifying anti-cancer agents and uses thereof
11/06/2012US8303995 Nitrite formulations and their use as nitric oxide prodrugs
11/06/2012US8303991 Method of making particles for use in a pharmaceutical composition
11/06/2012US8303990 Nanophoresis by placing magnetic nanoparticles conjugated with lipids, proteins, hormones, antioxidants, free radical scavengers into a middle region of an ear; magnetically driving particles through a membrane into the fluid of the inner ear; diagnosis or prophylaxis of ear disorders
11/06/2012US8303987 Pharmaceutical compositions comprising fluvastatin
11/06/2012US8303986 Hydrophilic/lipophilic polymeric matrix dosage formulation
11/06/2012US8303978 Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
11/06/2012US8303975 Implants for administering substances and methods of producing implants
11/06/2012US8303949 Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
11/06/2012US8303944 Hepatitis C virus inhibitors
11/06/2012US8303943 Ampholytic copolymer based on quaternized nitrogen-containing monomers
11/06/2012US8303933 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
11/06/2012US8303932 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
11/06/2012CA2710409C 6h-dibenz0 [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
11/06/2012CA2661987C Process for the preparation of sevelamer hydrochloride and formulation thereof
11/06/2012CA2607250C Polyethylene glycol colonic purgative composition
11/06/2012CA2563609C Pharmaceutical compositions for acute glucocorticoid therapy
11/06/2012CA2561868C Modified polynucleotides for reducing off-target effects in rna interference
11/06/2012CA2558195C 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
11/06/2012CA2551178C Polycyclic agents for the treatment of respiratory syncytial virus infections
11/06/2012CA2551043C The use of cystine or cysteine for the prevention and treatment of oxidative stress caused by haemodialysis and of acute or chronic kidney diseases
11/06/2012CA2538255C Cyanoacrylate monomer formulation containing diiodomethyl-p-tolylsulfone
11/06/2012CA2533591C Method for treatment of sores and lesions of the skin
11/06/2012CA2518282C Methods of improving skin quality
11/06/2012CA2498143C Antimicrobial composition and method for use
11/06/2012CA2497973C Antibiotic microspheres for treatment of infections and osteomyelitis
11/06/2012CA2497921C Vaginal health products
11/06/2012CA2495685C Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
11/06/2012CA2493083C Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors
11/06/2012CA2450257C Method of determining a chemotherapeutic regimen based on glutathione-s-transferase pi expression
11/06/2012CA2412790C Liposomal antineoplastic drugs and uses thereof
11/06/2012CA2302743C Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces
11/04/2012CA2766630A1 Anti-wart pharmaceutical composition and method for treating wart
11/02/2012CA2775624A1 New association between 4-{ 3-(cis-hexahydrocyclopenta (c) pyrrol -2 (1h)-yl ) propoxy } benzamide and an acetylcholinesterase inhibitor and the pharmacological composition withinthis association
11/01/2012WO2012149566A2 Anti-hiv group i introns and a uses thereof in treating hiv infections
11/01/2012WO2012149557A1 miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION
11/01/2012WO2012149547A1 Methods of treating hemoglobinopathies
11/01/2012WO2012149546A2 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
11/01/2012WO2012149540A1 Inhibitors of histone deacetylase
11/01/2012WO2012149535A1 The use of angiotensin ii (at ii) type 1 receptor antagonist in the therapeutic treatment of autism
11/01/2012WO2012149528A1 Inhibitors of inducible form of 6-phosphofructose-2-kinase
11/01/2012WO2012149495A1 Modulation of apolipoprotein ciii (apociii) expression
11/01/2012WO2012149478A2 Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
11/01/2012WO2012149472A2 Methods, compositions, and kits for treating and preventing neurological conditions
11/01/2012WO2012149454A2 Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use
11/01/2012WO2012149452A1 Compounds, formulations, and methods of protein kinase c inhibition
11/01/2012WO2012149451A1 Intravascular delivery of nanoparticle compositions and uses thereof
11/01/2012WO2012149419A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
11/01/2012WO2012149413A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
11/01/2012WO2012149411A1 Controlled release of immunosuppressants from synthetic nanocarriers
11/01/2012WO2012149406A2 Assessing and treating humans with long qt syndrome
11/01/2012WO2012149393A2 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
11/01/2012WO2012149358A1 Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
11/01/2012WO2012149353A1 Lactulose for bowel evacuation
11/01/2012WO2012149352A1 Fatty acid guanidine and salicylate guanidine derivatives and their uses
11/01/2012WO2012149349A2 Prophylaxis and treatment of enteropathogenic bacterial infection
11/01/2012WO2012149342A1 Mouse model for avm
11/01/2012WO2012149335A2 Small molecule inhibitors of rgs proteins
11/01/2012WO2012149326A1 Layer processing for pharmaceuticals
11/01/2012WO2012149308A1 Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
11/01/2012WO2012149301A2 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/2012WO2012149295A2 Methods of administering anatabine to treat autism spectrum disorders and seizure disorders
11/01/2012WO2012149287A1 Solvent cast film sustained release latanoprost implant
11/01/2012WO2012149285A1 Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
11/01/2012WO2012149282A2 Tolerogenic synthetic nanocarriers for generating cd8+regulatory t cells
11/01/2012WO2012149280A2 Novel tricyclic compounds
11/01/2012WO2012149278A1 Sustained release latanoprost implant
11/01/2012WO2012149268A1 Tolerogenic synthetic nanocarriers for allergy therapy
11/01/2012WO2012149267A1 Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits
11/01/2012WO2012149265A2 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/2012WO2012149259A1 Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/2012WO2012149255A2 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/2012WO2012149252A2 Tolerogenic synthetic nanocarriers
11/01/2012WO2012149251A1 Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
11/01/2012WO2012149247A2 Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use
11/01/2012WO2012149236A1 Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
11/01/2012WO2012149218A2 Antagonists of trpv1 receptor
11/01/2012WO2012149186A2 Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
11/01/2012WO2012149160A2 Viruses modified with unnatural moieties and methods of use thereof
11/01/2012WO2012149157A2 Heterocyclic compounds for the inhibition of pask
11/01/2012WO2012149136A1 Production and delivery of a stable collagen
11/01/2012WO2012149113A1 Method of treating dyskinesia
11/01/2012WO2012149106A1 Compositions and methods for increasing proliferation of adult salivary stem cells
11/01/2012WO2012149102A1 Novel compounds as wip1 inhibitors
11/01/2012WO2012149097A2 Guanidylimidazole and guanidylimidazoline derivatives as antimalarial agents, synthesis of and methods of use thereof
11/01/2012WO2012149093A1 2-guanidino-4-oxo-imidazoline derivatives as antimalarial agents, synthesis and methods of use thereof
11/01/2012WO2012149083A1 Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
11/01/2012WO2012149049A1 Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of mycobacterium tuberculosis
11/01/2012WO2012148998A1 Use of uridine and deoxyuridine to treat folate-responsive pathologies
11/01/2012WO2012148994A1 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
11/01/2012WO2012148930A2 Oxidative retinal diseases
11/01/2012WO2012148929A2 Disorders implicating pufa oxidation
11/01/2012WO2012148927A2 Impaired energy processing disorders and mitochondrial deficiency
11/01/2012WO2012148926A2 Neurodegenerative disorders and muscle diseases implicating pufas
11/01/2012WO2012148889A1 Inhibitors of human apurinic/apyrimidinic endonuclease 1
11/01/2012WO2012148887A2 Acute cognitive and mood effects of plant polysaccharides in adult human subjects
1 ... 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 ... 7860